Meclonazepam (Ro11-3128 or 3-methylclonazepam) is a benzodiazepine derivative. It exerts anxiolytic activity. Meclonazepam demonstrated anti-schistosomal action, it causes spastic paralysis, calcium influx and tegumental disruption in the parasites. Contracturant effect of meclonazepam is not a result of its binding to the worm benzodiazepine binding sites.

Mebenoside is an anti-inflammatory agent.

Mantabegron is an adamantane derivative with β3-adrenoreceptor agonist activity.

Zoleprodolol was developed as an adrenoreceptor antagonist. Information about the current use of this compound is not available.

Stevaladil is a pregnanediol derivative patented by Shionogi & Co., Ltd. as antiparasitic agent

Orvepitant is a novel generation brain penetrant, selective and potent, small molecule NK-1 receptor antagonist. Orvepitant’s (GW823296) mode of action and developability characteristics made it a suitable development candidate for the treatment of common anxiety disorders, posttraumatic stress disorder and major depressive disorder. It’s in phase II clinical trials as an effective inhibitor of itch-associated response.

Halonamine was studied as an antiparkinsonian agent.

Hexacyclonic Acid (aka gevilon) has been clinically demonstrated to produce hypolipidemic effects. It has been investigated as a treatment for coronary heart disease, and hypertensive disease with severe lipid metabolic disturbances. Gevilon has been found to have a hypolipidemic effect in reducing the levels of total cholesterol, beta-cholesterol, triglycerides, increasing alpha-cholesterol levels and normalizing the atherogenicity coefficient; especially in patients with Type IIb dyslipoproteinemia.